Selecta Biosciences Appoints Blaine Davis as Main Monetary Officer

WATERTOWN, Mass., Nov. 28, 2022 (World NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology business leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune illnesses, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, introduced the appointment of Blaine Davis as Main Monetary Officer, productive nowadays, November 28, 2022.

“Blaine is a remarkably achieved biopharmaceutical govt with verified fiscal and company advancement knowledge,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are making ready for a amount of essential opportunity milestones across our pipeline together with our expected Stage 3 readout in serious refractory gout, our anticipated Period 1/2 trial initiation in methylmalonic acidemia, and our planned IL-2 prospect collection for the treatment method of autoimmune disease with ImmTOR-IL. We are delighted to welcome Blaine to the group as we look for to choose this possibly generational leap ahead for our precision immune tolerance system and provide on our mission to restore pure immune tolerance in individuals struggling from debilitating disorders. Blaine’s impressive monitor record will make him an suitable fit for Selecta at this essential inflection stage.”

Mr. Davis included, “I am thrilled to be part of the Selecta crew at this pivotal second in the company’s progress trajectory. I glance forward to bringing my experience to Selecta and operating closely with the full group to attain our purpose of delivering prolonged-term benefit for shareholders and ultimately improving the life of our clients.”

Mr. Davis provides a lot more than 25 a long time of knowledge in investor relations, business enterprise growth, corporate affairs and revenue and advertising and marketing at life sciences companies, with a unique target on unusual diseases. Prior to signing up for Selecta, Mr. Davis served as Main Monetary Officer of Protara Therapeutics, Inc. where by he designed the finance function from the ground up across all money verticals. Previously, he served as Vice President, Head of Investor Relations and Corporate Communications at Insmed Included and held a number of government leadership positions at Endo Global plc, including Senior Vice President and Basic Supervisor, Specialty Prescription drugs President of Endo Ventures and Senior Vice President, Trader Relations and Company Communications. Prior to his tenure at Endo Global plc, Mr. Davis held a amount of roles in Company Progress and Investor Relations at Bristol-Myers Squibb Enterprise. Mr. Davis retains a B.A. in Biology and Psychology from Middlebury School.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical phase biotechnology business leveraging its ImmTOR™ platform to create tolerogenic therapies that selectively mitigate undesirable immune responses. With a established skill to induce tolerance to extremely immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of lifetime-saving gene therapies, as very well as restore the body’s organic self-tolerance in autoimmune ailments. Selecta has a number of proprietary and partnered courses in its pipeline targeted on enzyme therapies, gene therapies, and autoimmune illnesses. Selecta Biosciences is headquartered in the Greater Boston area. For far more facts, remember to visit